Skip to main content
S 4672 116th Congress Senate Health Advisory bodies Blood and blood diseases Cell biology and embryology Congressional oversight Government studies and investigations Health programs administration and funding Medical research Organ and tissue donation and transplantation Research administration and funding

TRANSPLANT Act of 2020

Introduced: September 23, 2020 Introduced by: Reed, Jack Democratic · Rhode Island See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 23, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S5835)
Sep 23, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2020 or the TRANSPLANT Act of 2020

This bill modifies and reauthorizes through FY2025 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also requires research and other activities related to stem cell therapies.

Specifically, the Department of Health and Human Services must conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments, and the National Institutes of Health must continue efforts to further the field of regenerative medicine using adult stem cells.

In addition, the Government Accountability Office must examine various issues related to the national blood stem cell workforce.

What's happening now September 23, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S5835)

 Related & companion bills 2
  • HR 3520 Related bill Stem Cell Therapeutic and Research Reauthorization Act of 2019
  • HR 4764 Related bill TRANSPLANT Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 2
All 2 Democratic 1 Republican 1
R
Scott, Tim
South Carolina · Sep 23, 2020
 D
Smith, Tina
Minnesota · Sep 23, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4672: TRANSPLANT Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-S-4672/
MLA
"S. 4672: TRANSPLANT Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-4672/.
Bluebook (legal)
S. 4672, 116th Cong. (2026), https://openamerica.io/bill/116-S-4672/.
Markdown link
[S. 4672: TRANSPLANT Act of 2020](https://openamerica.io/bill/116-S-4672/)
Report a problem